The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-21. Anything still debated is marked as such rather than presented as settled.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
=== Business === Protein Capture Science is a biotech start-up company commercializing a self-removing affinity tag technology for research and large-scale purifications of proteins. Wood and Izabela Gierach are co-founders of the company, based in Columbus, Ohio. The first line of the iCapTag products for protein purification was showcased in the Industry Innovators 2021-2022 Issue of the journal BioProcess International. Protein Capture Science was recently awarded several grants and funding, including highly competitive The Ohio Third Frontier Technology Validation and Start-Up Fund and the Concept Fund for extraordinary technologies by the Department of Development, State of Ohio.
=== 21st century global initiatives === Starting around 2009, there was renewed international media and political attention focused on malnutrition. This resulted in part from spikes in food prices and the 2008 financial crisis. Additionally, there was an emerging consensus that combating malnutrition is one of the most cost-effective ways to contribute to development. This led to the 2010 launch of the UN's Scaling up Nutrition movement (SUN). In April 2012, a number of countries signed the Food Assistance Convention, the world's first legally binding international agreement on food aid. The following month, the Copenhagen Consensus recommended that politicians and private sector philanthropists should prioritize interventions against hunger and malnutrition to maximize the effectiveness of aid spending. The Consensus recommended prioritizing these interventions ahead of any others, including the fights against malaria and AIDS. In June 2015, the European Union and the Bill & Melinda Gates Foundation launched a partnership to combat undernutrition, especially in children. The program was first implemented in Bangladesh, Burundi, Ethiopia, Kenya, Laos and Niger. It aimed to help these countries improve information and analysis about nutrition, enabling them to develop effective national nutrition policies. Also in 2015, the UN's Food and Agriculture Organization created a partnership aimed at ending hunger in Africa by 2025. The African Union's Comprehensive Africa Agriculture Development Programme (CAADP) provided the framework for the partnership.
Forced to retreat, Alexios ceded the city of Dyrrachium to the Count of the Tent (or Byzantine provincial administrators) mobilizing from Arbanon (i.e., ἐξ Ἀρβάνων ὁρμωμένω Κομισκόρτη; the term Κομισκόρτη is short for κόμης της κόρτης meaning "Count of the Tent"). The city's garrison resisted until February 1082, when Dyrrachium was betrayed to the Normans by the Venetian and Amalfitan merchants who had settled there. The Normans were now free to penetrate into the hinterland; they took Ioannina and some minor cities in southwestern Macedonia and Thessaly before appearing at the gates of Thessalonica. Dissension among the high ranks coerced the Normans to retreat to Italy. They lost Dyrrachium, Valona, and Butrint in 1085, after the death of Robert. A few years after the First Crusade, in 1107, the Normans under the command of Bohemond, Robert's son, landed in Valona and besieged Dyrrachium using the most sophisticated military equipment of the time, but to no avail. Meanwhile, they occupied Petrela, the citadel of Mili at the banks of the river Deabolis, Gllavenica (Ballsh), Kanina and Jericho. This time, the Albanians sided with the Normans, dissatisfied by the heavy taxes the Byzantines had imposed upon them. With their help, the Normans secured the Arbanon passes and opened their way to Dibra. The lack of supplies, disease and Byzantine resistance forced Bohemond to retreat from his campaign and sign a peace treaty with the Byzantines in the city of Deabolis.
=== Expansion and loss === Typical GSH-Px and superoxide dismutase enzymes requrire trace elements including selenium, vanadium, magnesium, copper, and zinc. These elements tend to be abundant in marine environments but can be lacking in some terrestrial mineral-deficient areas. Organisms have accordingly expanded or reduced their seleno-proteomes (arsenal of selenoproteins) to adapt to the situation. As land plants adapted to the terrestrial environment from about 500 million years ago, they too faced the problem of a lack of these elements. Accordingly, most land plants do not produce selenoproteins. For their anti-oxidation needs, they slowly optimized the production of "new" endogenous antioxidants such as ascorbic acid (Vitamin C), polyphenols (including flavonoids), tocopherols, etc. A few of these appeared more recently, in the last 50–200 million years, in fruits and flowers of angiosperm plants. In fact, the angiosperms (the dominant type of plant today) and most of their antioxidant pigments evolved during the late Jurassic period. The vertebrates of 500 million years ago were marine fishes. They opted to expand their seleno-proteomes, most notably evolving a thyroid gland with high concentration of selenium and iodine and associated systems. A group of them, the tetrapoda, later adapted to life on land but retained many of the ancestral selenoproteins.
Sources: en.wikipedia.org
=== Body wall === The body wall layers include a thin cuticle covering, an epidermis consisting of a single layer of cells, a thick dermis formed of connective tissue, a thin coelomic myoepithelial layer for the muscles, and a peritoneum which lines the body cavity. The dermis contains an endoskeleton of calcium carbonate components known as ossicles. These are honeycomb-like structures composed of calcite microcrystals arranged in a lattice. They vary in form, from flat plates to granules to spines, and cover the aboral (top) surface. Some are specialised structures such as the madreporite (the entrance to the water vascular system), pedicellariae, and paxillae. Paxillae are umbrella-like structures found on starfish that live buried in substrate. The edges of adjacent paxillae meet to form a false cuticle with a water cavity beneath in which the madreporite and delicate gill structures are protected. The ossicles are located under the epidermal layer, even those emerging externally. Several groups of starfish, including Valvatida and Forcipulatida, possess pedicellariae. These are scissor-like ossicles at the tip of the spine which displace organisms from resting on the starfish's surface. Some species like Labidiaster annulatus and Novodinia antillensis use their pedicellariae to catch prey. There may also be papulae, thin-walled protrusions of the body cavity that reach through the body wall into the surrounding water. These serve a respiratory function.
The Cherokee Nation also has the right to appoint a delegate to the U.S. House of Representatives, per the 1835 Treaty of New Echota. In 2019, Kimberly Teehee was appointed the first ever delegate to the U.S. House of Representatives from the Cherokee Nation, in accordance with the 1835 treaty, though Congress has not yet seated her.
=== 2000s === Hudson was named chairman of Sonic Corp. in January 2000. In September of 2002, Sonic Corporation introduced PartnerNet to its franchisees, an intranet array of services that for the first time, digitally linked all Sonic Drive-in locations to Sonic Corporation. The new intranet was via Hughes Satellite Services and provided advancements like credit card processing and video training. The compulsory service package was headlined with the introduction of Sonic Live Radio by StudioStream Signature Sound, featuring a toll-free request line, 866-SONIC-FM, and live on-air personalities. The live radio style was first of its kind for corporate America, later emulated by the likes of Walmart. Sonic Live Radio, in beta since 2001, was released to all locations in February 2003. Sonic gained further attention in 2003 following the release of comedic reality show The Simple Life starring Paris Hilton and Nicole Richie. Hilton and Richie, previously with no experience in having a job, had to work in a Sonic site in Altus, Arkansas. Celebrating its 50th birthday in 2003, Sonic briefly added the Birthday Cake Shake to the menu. As a part of the anniversary celebration, Pickle-O's made another appearance as a recurring item. Development milestones celebrated in the 2000s include the opening of the 3,000th Sonic Drive-In in Shawnee, Oklahoma, and the 3,500th Sonic Drive-In in the Chicago market (Algonquin, Illinois). In October 2004, President Pattye Moore stepped down to spend more time with her family.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.